MarketCapExport financials
Nurix Therapeutics (NRIX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Nurix Therapeutics Income Statement 2025-2011 | NRIX
Brief overview of financial results at Nurix Therapeutics
The figures are compared over a five-year interval. Revenue reported by Nurix Therapeutics was 17.8 million dollars at the beginning of the period and 84 million dollars at the end. The five-year change reached +371.3%, while CAGR stood at 36.3%. Sales grew at a rate typical of a strong expansion phase.
EBITDA changed from −$62.8 million to −$277 million (−340.9%). EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from −352.4% to −329.8%. Higher profitability strengthens the quality of operating growth.
Net income moved from −$43.2 million at the start to −$264 million at the end. Profitability deteriorated further over the five years.
Over the period, capitalization shifted from 1.1 billion dollars to 1.6 billion dollars (+41.6%). Investors responded cautiously to the improvement in the business.
What the figures show
The five-year picture requires weighing both strengths and weaknesses. The positive side is supported by an improving EBITDA margin and sales growth. The weaker side of the profile includes a weaker final result and a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Nurix Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.57 B | 1.31 B | 538 M | 548 M | 1.24 B | 1.11 B | - | - | - | - | - | - | - | - | - |
Shares |
86.7 M | 67.1 M | 54.3 M | 48.6 M | 42.9 M | 31.4 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
18.1 | 19.6 | 9.9 | 11.3 | 28.9 | 32.9 | - | - | - | - | - | - | - | - | - |
Net Income |
-264 M | -194 M | -144 M | -180 M | -117 M | -43.2 M | -21.7 M | -9.43 M | - | - | - | - | - | - | - |
Revenue |
84 M | 54.5 M | 77 M | 38.6 M | 29.8 M | 17.8 M | 31.1 M | 37.4 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 17.8 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-286 M | -213 M | -155 M | -184 M | -118 M | -65 M | -22.2 M | - | - | - | - | - | - | - | - |
EBITDA |
-277 M | -204 M | -148 M | -179 M | -115 M | -62.8 M | -19.9 M | -6.75 M | - | - | - | - | - | - | - |
Operating Expenses |
370 M | 268 M | 232 M | 222 M | 148 M | 82.8 M | 53.4 M | 47.2 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
52.7 M | 45.9 M | 42.9 M | 38 M | 31.2 M | 16.3 M | 8.33 M | 6.67 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Nurix Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
84.2 M | 111 M | 110 M | 102 M | 84.2 M | 83.9 M | 83.6 M | 75.9 M | 72.8 M | 62.4 M | 54.9 M | 48.7 M | 54.4 M | 54.3 M | 54 M | 47.2 M | 50.9 M | 44.9 M | 44.7 M | 44.7 M | 44.4 M | 43.8 M | 38.8 M | 38.7 M | 16.9 M | 3.73 M | 3.54 M | 3.81 M | 3.67 M | 3.43 M | 3.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-56.4 M | -89.5 M | -87.2 M | - | -86.4 M | -43.5 M | -56.4 M | - | -49 M | -44.5 M | -41.5 M | - | -37 M | -24.3 M | -40.7 M | - | -45.7 M | -45.4 M | -42.5 M | - | -28.8 M | -26.4 M | -24.3 M | -19.9 M | -18.5 M | 7.58 M | -12.4 M | -13.5 M | -2.43 M | -3.07 M | -2.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
7.89 M | 9.04 M | 6.25 M | - | 7.89 M | 44.1 M | 18.5 M | - | 12.6 M | 12.1 M | 16.6 M | - | 18.5 M | 30.7 M | 12.7 M | - | 10.8 M | 11.4 M | 9.62 M | - | 10.3 M | 7.09 M | 5.01 M | 6.69 M | 4.08 M | 4.18 M | 2.86 M | 1.86 M | 10.6 M | 9.44 M | 9.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-91.4 M | -94.2 M | -92.5 M | - | -91.4 M | -48.3 M | -62.9 M | - | -54.6 M | -48.5 M | -45.2 M | - | -40 M | -26.8 M | -43 M | - | -46.7 M | -45.7 M | -42.7 M | - | -29 M | -26.4 M | -24.5 M | - | -19.2 M | -13.2 M | -12.6 M | - | -2.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-91.4 M | -89.8 M | -90.3 M | - | - | - | -60.5 M | - | - | - | -43.2 M | - | - | - | -41.2 M | - | -45.2 M | -44.4 M | -41.8 M | - | -28.3 M | -25.8 M | -23.9 M | - | -18.6 M | -12.7 M | -12.1 M | - | -2.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
99.3 M | 103 M | 98.7 M | - | 99.3 M | 92.4 M | 81.3 M | - | 67.2 M | 60.6 M | 61.8 M | - | 58.5 M | 57.4 M | 55.6 M | - | 57.5 M | 57.1 M | 52.4 M | - | 39.2 M | 33.5 M | 29.5 M | - | 23.3 M | 17.4 M | 15.4 M | - | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
13.2 M | 15.6 M | 14.6 M | - | 13.2 M | 14.3 M | 11.7 M | - | 11.7 M | 11.7 M | 11.8 M | - | 10.6 M | 11.7 M | 9.82 M | - | 9.75 M | 9.65 M | 9.23 M | - | 8.34 M | 7.51 M | 6.53 M | - | 4.34 M | 3.27 M | 2.45 M | - | 2.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Nurix Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
